Jeff Galvin is the CEO and Founder of American Gene Technologies™ (AGT). He earned his BA degree in Economics from Harvard in 1981 and has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies, including one in the medical-technology arena that was sold to Varian, the leading maker of linear accelerators used in cancer therapy. Following his startup experience, he retired to become an Angel Investor in real estate and high tech. He came out of retirement to found and fund AGT after meeting Roscoe Brady at NIH.
Jeff Galvin, CEO and Founder at American Gene Technologies™ (AGT)
Subscribe to Our Newsletter
Get the latest on clinical trials in Latin America — regulatory updates, market access strategies & industry trends. Delivered straight to your inbox.
Email has been submitted.
Recent Episodes
- Allison Komiyama, CEO and Founder at Bluestocking Health, LLC
- Daniel Zequeto, Founder & CEO at ODC Life Sciences
- Satabhisa Mukhopadhyay, Founder & Chief Scientist at 4D Path Inc
- Deborah Morley, Director CV Strategy and Delivery at RQM+
- Leonara vidal, Global Clinical Affairs Lead at Gentell
- Gerardo Noriega, Presiden & CEO at PercAssist, Inc
- Matt DeNardo, Chief Product Officer at Axoft
- Daniel Chen, Founder and CEO at Synthetic Design Lab
- Shareef Mahdavi, Founder at PX Movement
- See all →